STAGE 4 LUNG
CANCER TREATMENT
Stage 4 NSCLC has more approved targeted treatment options than any other solid tumour. The challenge is ensuring molecular testing happens before the first treatment decision -- not after.
Stage 4 NSCLC Treatment by Molecular Subgroup
| Alteration | Frequency | Preferred First-Line Agent | Key Notes |
|---|---|---|---|
| EGFR mutations | 10-15% Western; up to 50% Asian | Osimertinib | Oral tablet; median PFS >18 months; CNS active; approved adjuvant post-resection |
| ALK fusions | 3-5% | Lorlatinib or alectinib | Among most treatment-responsive subgroups in oncology; lorlatinib covers most resistance |
| KRAS G12C | ~13% | Sotorasib or adagrasib | First-ever approved KRAS inhibitors; historically undruggable for 40 years |
| MET exon 14 skipping | 3-4% | Capmatinib or tepotinib | More common in older patients and never-smokers |
| RET fusions | 1-2% | Selpercatinib or pralsetinib | Strong response rates; CNS penetration |
| HER2 mutations (exon 20) | 2-3% | Trastuzumab deruxtecan (T-DXd) | Distinct from HER2 amplification |
| High PD-L1, no driver mutation | Variable | Pembrolizumab monotherapy (PD-L1 >=50%) | Chemo-immunotherapy combinations for lower PD-L1 or squamous histology |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Stage 4 Lung Cancer Treatment for Your Molecular Profile?
CancerFax reviews your NSCLC molecular report and connects you with specialist lung oncologists experienced in each approved targeted therapy.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.